At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
oral metronidazole +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis
In Brief
A Phase 2 clinical trial evaluating oral metronidazole, neo penotran forte, and 1 other intervention for Trichomonas Vaginitis. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The investigators are trying a combination vaginal product of higher dose metronidazole combined with miconazole to see if it is effective in treating vaginal trichomonas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTrichomonas Vaginitis
CountriesUnited States
CollaboratorsEmbil Pharmaceutical Co. Ltd
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartDec 2011
Primary CompletionAug 2012
Study CompletionJan 2013
TodayJul 2026
First PostedMay 26, 2011
Enrollment StartDec 1, 2011
Primary CompletionAug 1, 2012
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.1 years ago
Interventions
oral metronidazoledrug
2 gm oral once
neo penotran fortedrug
neo penotran forte intravaginal twice a day for 7 days
neo penotran forte once a daydrug
neo penotran forte intravaginally once a day for 7 days